Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference
May 04 2023 - 4:01PM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers for the treatment of
Alzheimer’s disease, announced today that management will
participate in a fireside chat at the 2023 Bank of America
Healthcare Conference on Thursday, May 11,
2023 at 8:00 a.m. PT (11:00 a.m. ET). The live webcast
may be accessed under the Investors tab
on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with clinical
operations based in Carmel, IN, is a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers (AβOs) for the
treatment of Alzheimer’s disease (AD). Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are early and persistent triggers of Alzheimer’s disease
pathology. Acumen is currently focused on advancing its
investigational product candidate, ACU193, a humanized monoclonal
antibody that selectively targets toxic soluble AβOs in
INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s
disease patients. For more information, visit
www.acumenpharm.com.
Investors: Alex Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jul 2023 to Jul 2024